Trial Profile
Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem) in Patients With Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Invimestrocel (Primary)
- Indications Stroke
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TREASURE
- Sponsors Healios
- 16 Jan 2024 Results reporting multiStem safety and efficacy findings from this trial in patients treated within 18 to 36 hours after ischemic stroke onset published in the JAMA Neurology
- 15 Jan 2024 Status changed from active, no longer recruiting to completed.
- 09 Jan 2023 According to Athersys media release, in November 2022 the company conducted a meeting of Key Opinion Leaders (KOL's) to discuss the potential changes to given clinical findings from this study.